SCI Abstract

search
+
Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study
Hemophagocytic lymphohistiocytosis in HIV-related lymphomas: a multicentre retrospective cohort study
Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms ...
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors
The ASC4OPT non-comparative phase 3b study (NCT04948333) evaluates asciminib once daily (QD) or twice daily (BID) in chron...
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia
Activation of oncogenes by hijacking immunoglobulin gene loci (IG) enhancers via chromosomal translocation is a common pat...
Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia
Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia
Within our cohort, one patient was diagnosed with NS at birth and developed CML in blast phase (CML-BP) at 1.4 years of ag...
A small proportion of CD8 T cells expand robustly when stimulated with BCMAxCD3 bispecific T-cell engagers in vitro
A small proportion of CD8 T cells expand robustly when stimulated with BCMAxCD3 bispecific T-cell engagers in vitro
Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodríguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5...
Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use
Blinatumomab in pediatric acute lymphoblastic leukemia: current and future use
Treatment outcomes for pediatric acute lymphoblastic leukemia (ALL) have improved considerably, with overall survival rate...
Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease
Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease
Chronic myelomonocytic leukemia (CMML) is an MDS/MPN overlap neoplasm defined by monocytosis, clonal hematopoiesis, and ma...
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults
Development and validation of the predictive aplastic score system (PASS): a simplified tool to diagnose acquired aplastic anemia in adults
Acquired aplastic anemia (AA) can present similarly to inherited bone marrow failure syndromes (IBMFS) but treatment diffe...
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of...
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome
Competing interests GM-B declares research funding from IFM Therapeutics, Rigel ...
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model
Venetoclax plus azacitidine is recognized as standard of care for patients with acute myeloid leukemia (AML) ineligible fo...
Insights into germline predisposition to pediatric lymphoid malignancies
Insights into germline predisposition to pediatric lymphoid malignancies
Hematopoietic malignancies (HM) represent the most common form of pediatric cancer with lymphoid malignancies being the pr...
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
Waldschmidt JM, Rasche L, Kortüm KM, Einsele H. Comprehensive review of bispecific antibody constructs in multiple myeloma...
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias
At present there is no metabolic characterization of acute promyelocytic leukemia (APL). Pathognomonic of APL, PML::RAR ...
Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML
Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML
Pediatric acute myeloid leukemia (pAML) is a heterogeneous malignancy driven by diverse cytogenetic mutations. While ident...
A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia
A three-dimensional ex vivo model recapitulates in vivo features and drug resistance phenotypes in childhood acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) preferentially localizes in the bone marrow (BM) and displays recurrent patterns of med...
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML
The polycomb protein EZH2 is up-regulated in Chronic Myeloid Leukaemia (CML) and associated with transcriptional reprogram...
Modeling GATA2 deficiency in mice: the R396Q mutation disrupts normal hematopoiesis
Modeling GATA2 deficiency in mice: the R396Q mutation disrupts normal hematopoiesis
GATA2 deficiency is an autosomal dominant germline disorder of immune dysfunction and bone marrow failure with a high prop...
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
Off-label hypomethylating agents and venetoclax (HMA/VEN) are often used for relapsed and refractory (R/R) AML patients. H...
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies
The FLT3 gene frequently undergoes mutations in acute myeloid leukemia (AML), with internal tandem duplications (ITD) and ...
Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization
Multi-omic analysis of chronic myelomonocytic leukemia monocytes reveals metabolic and immune dysregulation leading to altered macrophage polarization
Chronic myelomonocytic leukemia (CMML) is a clonal myelodysplastic/myeloproliferative neoplasm characterized by persistent...
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis
Expression of CD2, CD25 and/or CD30 in extracutaneous mast cells (MC) is a minor diagnostic criterion for systemic mastocy...
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
In the MAIA study (median follow-up, 56.2 months), daratumumab plus lenalidomide and dexamethasone (D-Rd) significantly im...
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological disease originating from the malignant transfor...
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
Acute myeloid leukemia (AML) is a malignancy with a poor prognosis. The expansion of leukemic cells is associated with the...
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
Luigi (Gino) Chieco-Bianchi: a man linking hematological and virological research
Credit: Courtesy of G. PizzoloLuigi Chieco Bianchi, called Gino by his friends, died in Padua on June 23rd 20...
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is still an incurable disease, with many patients developing resistance to conventional...
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of ...
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group Trial AALL0232
Osteonecrosis is a significant toxicity of acute lymphoblastic leukemia (ALL) therapy. In retrospective analyses, superior...
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States
Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol ...
Load More
format_indent_increase